Physician profile
Danny E Thomason
NPI 1851352645
$9,457.83
in general payments reported to CMS, 2019-2025
55 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,261 · 2020: $462 · 2021: $76.98 · 2022: $1,093 · 2023: $1,680 · 2024: $2,133 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,535 · Education: $31.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,534.96 |
| Education | $31.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,552.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,076.71 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $810.76 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $557.26 | 2019-2025 | |
| Lilly USA, LLC | $507.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $422.88 | 2023-2025 | |
| Amgen INC. | $420.02 | 2019-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.93 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Glaxosmithkline, LLC. | $364.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $322.41 | 2019-2025 | Spravato |
| Amarin Pharma, INC. | $261.01 | 2019-2020 | |
| Corium, LLC | $250.22 | 2023-2024 | Azstarys |
| Insulet Corporation | $227.44 | 2025 | Omnipod |
| Abbott Laboratories | $218.79 | 2022-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $158.71 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Thomason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.